Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy
Rattachement africain : us, au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To evaluate the impact of surgical lymph node assessment for clinically apparent, stage I endometrioid endometrial adenocarcinoma meeting Mayo criteria for lymphadenectomy. METHODS: Patients with endometrioid endometrial adenocarcinoma meeting Mayo criteria for lymphadenectomy who underwent hysterectomy and lymphadenectomy were identified. Algorithms for adjuvant therapy with and without lymphadenectomy were developed utilizing NCCN guidelines, PORTEC 1, and PORTEC 2. Patients served as their own control to determine the frequency of treatment modification. RESULTS: A total of 357 patients were analyzed. Using our algorithms treatment modification would have occurred because of lymphadenectomy in 62.8% of patients if whole pelvic external beam radiation was used for patients meeting inclusion criteria for PORTEC 1. Treatment modification would have occurred in 16.2% of patients if vaginal brachytherapy was used for patients meeting the inclusion criteria for PORTEC 2. Of the total, 53.8% of patients meeting inclusion criteria for PORTEC 1 would have had a reduction in adjuvant therapy from whole pelvic radiotherapy to vaginal brachytherapy alone. Only 9.0% of patients would have adjuvant therapy increased to include external beam radiotherapy and chemotherapy based on the presence of positive lymph nodes. CONCLUSIONS: Applying standard adjuvant treatment algorithms to real patient data, surgical lymph node assessment appears to frequently alter treatment allocation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy
- Date Crossref
- 16/02/2021
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Cleveland Clinic Division of Gynecologic Oncology pays non établi dans la noticeÉtablissement de santé
-
Cleveland Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
Mercy Hospital for Women Department of Gynaecological Oncology pays non établi dans la noticeÉtablissement de santé
-
Cleveland Clinic Lerner College of Medicine pays non établi dans la noticeÉtablissement de santé
-
Quantitative BioSciences pays non établi dans la noticeOrganisation à but non lucratif
-
Department of Obstetrics and Gynecology and Women's Health Institute Division of Gynecologic Oncology pays non établi dans la noticeStructure de recherche
-
Department of Quantitative Health Sciences Lerner Research Institute Cleveland Ohio USA Department of Quantitative Health Sciences pays non établi dans la noticeStructure de recherche
Division of Gynecologic Oncology — Cleveland Clinic, Cleveland Foundation et Department of Gynaecological Oncology — Mercy Hospital for Women, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.